Compare BridgeBio Pharma Inc (BBIO) vs Intuit Inc. (INTU) Price & Performance

BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.

Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.

Intuit (INTU) trades at $282.43, up 2.72% today, with a bullish technical signal but mixed oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $12.8 exceeding expectations. Revenue grew to $18.83B in 2025, and net income margin expanded to 20.54%. However, the stock faces headwinds from multiple law firm investigations into securities fraud allegations related to TurboTax pricing, contributing to a 20% stock drop recently noted by Forbes on June 2, 2026.

The outlook is cautiously optimistic with a consensus price target of $422.88, implying significant upside. Analyst sentiment is 71% buy-rated, but risks include legal overhangs and competitive pressures. Long-term growth drivers like AI integration in Mailchimp and TurboTax Live support fundamentals, yet investors must weigh litigation uncertainties against strong profitability and cash flow trends.